IP Library Granted Patent US 11,407,736
Granted Patent B2
US 11,407,736 · App. 17/012,779 · Granted Aug 9, 2022

RIP1 inhibitory compounds and methods for making and using the same

Inventors: Yan Chen (Foster City, CA); Jiaxin Yu (Foster City, CA); Simon Shaw (Oakland, CA); Ihab Darwish (South San Franciso, CA); Vanessa Taylor (San Francisco, CA); Somasekhar Bhamidipati (Foster City, CA); Zhushou Luo (San Jose, CA); Rao Kolluri (Foster City, CA)
Assignee: Rigel Pharmaceuticals, Inc.
C07D401/14A61K31/553C07D267/02C07D401/12C07D403/12C07D403/14C07D405/14C07D413/12C07D413/14C07D471/08C07D487/04C07D491/107C07D493/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,407,736
App. No.
17/012,779
Granted
Aug 9, 2022
Kind
B2
Abstract

Disclosed herein are kinase inhibitory compounds, such as a receptor-interacting protein-1 (RIP1) kinase inhibitor compounds, as well as pharmaceutical compositions and combinations comprising such inhibitory compounds. The disclosed compounds, pharmaceutical compositions, and/or combinations may be used to treat or prevent a kinase-associated disease or condition, particularly a RIP1-associated disease or condition.

Claims (12)

1. A compound, having a formula

or a pharmaceutically acceptable salt thereof.

2. A compound, having a formula

or a pharmaceutically acceptable salt thereof.

3. The compound according to claim 1 which is:

4. The compound according to claim 2 which is:

5. A pharmaceutical composition, comprising a compound having the formula:

or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable excipient.

6. The pharmaceutical composition according to claim 5 wherein the compound is:

7. A pharmaceutical composition, comprising a compound having the formula:

or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable excipient.

8. The pharmaceutical composition according to claim 7 wherein the compound is:

Assignments (3)
SECURITY INTEREST Recorded May 8, 2026
From: RIGEL PHARMACEUTICALS, INC.
To: MIDCAP FUNDING IV TRUST
Reel/Frame 075576/0880 →
SECURITY INTEREST Recorded Aug 25, 2022
From: RIGEL PHARMACEUTICALS, INC.
To: MIDCAP FINANCIAL TRUST
Reel/Frame 061327/0712 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 23, 2021
From: CHEN, YAN; YU, JIAXIN; SHAW, SIMON; DARWISH, IHAB; TAYLOR, VANESSA; BHAMIDIPATI, SOMASEKHAR; LUO, ZHUSHOU; KOLLURI, RAO
To: RIGEL PHARMACEUTICALS, INC.
Reel/Frame 055684/0280 →
Continuity (7)
Provisional Application 62897223 · Sep 6, 2019
Provisional Application 62932404 · Nov 7, 2019
Provisional Application 63004290 · Apr 2, 2020
Provisional Application 63001016 · Mar 27, 2020
Provisional Application 63004301 · Apr 2, 2020
Provisional Application 63004319 · Apr 2, 2020
Related Publication 20210070743A1 · Mar 11, 2021
Cited By (2)
US 12,297,202 US 12,331,036